223 related articles for article (PubMed ID: 29220794)
1. O
Li Q; Zou P; Sun J; Chen L
Eur J Med Chem; 2018 Jan; 143():732-744. PubMed ID: 29220794
[TBL] [Abstract][Full Text] [Related]
2. Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
Fu J; Liu L; Huang Z; Lai Y; Ji H; Peng S; Tian J; Zhang Y
J Med Chem; 2013 Jun; 56(11):4641-55. PubMed ID: 23617697
[TBL] [Abstract][Full Text] [Related]
3. Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.
Sinha BK; Perera L; Cannon RE
Biomed Pharmacother; 2019 Dec; 120():109468. PubMed ID: 31605952
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells.
Tang X; Gu X; Ai H; Wang G; Peng H; Lai Y; Zhang Y
Bioorg Med Chem Lett; 2012 Jan; 22(2):801-5. PubMed ID: 22209486
[TBL] [Abstract][Full Text] [Related]
5. Novel NO-releasing plumbagin derivatives: Design, synthesis and evaluation of antiproliferative activity.
Bao N; Ou J; Xu M; Guan F; Shi W; Sun J; Chen L
Eur J Med Chem; 2017 Sep; 137():88-95. PubMed ID: 28558333
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents.
Zou ZH; Lan XB; Qian H; Huang WL; Li YM
Bioorg Med Chem Lett; 2011 Oct; 21(19):5934-8. PubMed ID: 21843940
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and multidrug resistance reversal activity evaluation of 8-oxocoptisine derivatives.
Wu JB; Lei F; Cui XJ; He Y; Hai L; Zhang J; Wu Y
Med Chem; 2012 Jul; 8(4):742-8. PubMed ID: 22548337
[TBL] [Abstract][Full Text] [Related]
8. Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies.
Xu S; Wang G; Lin Y; Zhang Y; Pei L; Yao H; Hu M; Qiu Y; Huang Z; Zhang Y; Xu J
Bioorg Med Chem Lett; 2016 Jun; 26(12):2795-2800. PubMed ID: 27158140
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E
Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572
[TBL] [Abstract][Full Text] [Related]
10. Artemisinin-indole and artemisinin-imidazole hybrids: Synthesis, cytotoxic evaluation and reversal effects on multidrug resistance in MCF-7/ADR cells.
Hu Y; Li N; Zhang J; Wang Y; Chen L; Sun J
Bioorg Med Chem Lett; 2019 May; 29(9):1138-1142. PubMed ID: 30837097
[TBL] [Abstract][Full Text] [Related]
11. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
Shami PJ; Saavedra JE; Wang LY; Bonifant CL; Diwan BA; Singh SV; Gu Y; Fox SD; Buzard GS; Citro ML; Waterhouse DJ; Davies KM; Ji X; Keefer LK
Mol Cancer Ther; 2003 Apr; 2(4):409-17. PubMed ID: 12700285
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo.
Shami PJ; Saavedra JE; Bonifant CL; Chu J; Udupi V; Malaviya S; Carr BI; Kar S; Wang M; Jia L; Ji X; Keefer LK
J Med Chem; 2006 Jul; 49(14):4356-66. PubMed ID: 16821795
[TBL] [Abstract][Full Text] [Related]
13. Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
Zhong H; Zhao X; Zuo Z; Sun J; Yao Y; Wang T; Liu D; Zhao L
Eur J Med Chem; 2016 Jan; 108():720-729. PubMed ID: 26741854
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anticancer activity of novel quinoline-docetaxel analogues.
Chen M; Chen H; Ma J; Liu X; Zhang S
Bioorg Med Chem Lett; 2014 Jul; 24(13):2867-70. PubMed ID: 24835987
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance.
Zha GF; Qin HL; Youssif BGM; Amjad MW; Raja MAG; Abdelazeem AH; Bukhari SNA
Eur J Med Chem; 2017 Jul; 135():34-48. PubMed ID: 28431353
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.
Teodori E; Contino M; Riganti C; Bartolucci G; Braconi L; Manetti D; Romanelli MN; Trezza A; Athanasios A; Spiga O; Perrone MG; Giampietro R; Gazzano E; Salerno M; Colabufo NA; Dei S
Eur J Med Chem; 2019 Nov; 182():111655. PubMed ID: 31494468
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
Li YS; Yang X; Zhao DS; Cai Y; Huang Z; Wu R; Wang SJ; Liu GJ; Wang J; Bao XZ; Ye XY; Wei B; Cui ZN; Wang H
Eur J Med Chem; 2021 Apr; 216():113336. PubMed ID: 33725657
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and cytotoxic evaluation of nitric oxide-releasing derivatives of isosteviol.
Liu Y; Wang T; Ling Y; Bao N; Shi W; Chen L; Sun J
Chem Biol Drug Des; 2017 Sep; 90(3):473-477. PubMed ID: 28122177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
